What is the recommended multimodal management strategy for chronic pain (pain persisting > three months)?

Multimodal Management of Chronic Pain

Nonpharmacologic therapy and non-opioid pharmacologic therapy are the preferred first-line treatments for chronic pain, with opioids reserved only as second- or third-line options when benefits clearly outweigh risks. 1

Definition and Scope

Chronic pain is defined as pain persisting beyond 3 months or past normal tissue healing time 2. This guideline applies to chronic noncancer pain outside of palliative care and end-of-life settings.

First-Line Treatment Strategy

Nonpharmacologic Interventions (Start Here)

Physical activity is the foundation for managing chronic low back pain and osteoarthritis, with clear long-term evidence of benefit 3. The following nonpharmacologic therapies have strong evidence:

• Cognitive Behavioral Therapy (CBT): Strongly recommended for chronic pain management, promoting adaptive behaviors and addressing maladaptive pain responses 4
• Physical and occupational therapy: Recommended for chronic pain 4
• Yoga: Recommended specifically for chronic neck/back pain, headache, rheumatoid arthritis, and general musculoskeletal pain 4
• Hypnosis: Recommended for neuropathic pain 4

Interdisciplinary multimodal pain treatment (IMPT) programs should be utilized when available, as they provide durable improvements in physical, emotional, and social functioning with sustained benefits at 12+ months follow-up 5, 6.

Pharmacologic First-Line Options

For musculoskeletal pain:

• Acetaminophen and NSAIDs are first-line agents 4
• Acetaminophen has fewer side effects than NSAIDs (typical dosing 4g/day; reduce for liver disease) 4
• COX-2 NSAIDs have decreased GI risk but increased cardiovascular risk 4

For neuropathic pain:

• Gabapentin is the first-line oral pharmacological treatment (titrate to 2400 mg/day in divided doses) 4
• If inadequate response to gabapentin, consider serotonin-norepinephrine reuptake inhibitors (SNRIs) or tricyclic antidepressants 4
• Topical capsaicin (8% dermal patch for 30 minutes) provides pain relief for at least 12 weeks 4

Second/Third-Line: When to Consider Opioids

Opioids should NOT be first-line agents for chronic pain management 4. Consider opioids only when:

1. Patients fail first-line therapies
2. Report moderate-to-severe pain with functional impairment
3. Expected benefits for pain AND function outweigh risks 4, 1, 4

Critical Opioid Prescribing Requirements

Before initiating opioids:

• Establish realistic treatment goals for pain and function 1
• Discuss known risks and benefits explicitly 1
• Assess risk factors for opioid-related harms (history of substance use disorder, overdose, concurrent benzodiazepine use) 1
• Review prescription drug monitoring program (PDMP) data 1
• Perform baseline urine drug testing 1
• Create an opioid patient-provider agreement 4

Prescribing specifics:

• Start with immediate-release opioids (NOT extended-release/long-acting) 1
• Use the lowest effective dose 1
• Carefully reassess when reaching 50 MME/day 1
• Avoid exceeding 90 MME/day or carefully justify if necessary 1
• For neuropathic pain: consider combining morphine with gabapentin for additive effects 4

Monitoring requirements:

• Evaluate benefits and harms within 1-4 weeks of starting or dose escalation 1
• Re-evaluate every 3 months or more frequently 1
• Review PDMP data periodically (every prescription to every 3 months) 1
• Perform urine drug testing at least annually 1
• Never use UDT results in isolation to discharge patients—combine with clinical data 4

Discontinuation criteria:

• If benefits do not outweigh harms, optimize other therapies and taper opioids 1

Interventions NOT Recommended

Strong recommendations AGAINST the following for chronic spine pain 7:

• Joint radiofrequency ablation with or without injections
• Epidural injections of local anesthetic, steroids, or combinations
• Joint-targeted injections
• Intramuscular injections of local anesthetic

Critical Safety Measures

• Avoid concurrent opioid and benzodiazepine prescribing 1
• Consider offering naloxone when risk factors present (history of overdose, substance use disorder, ≥50 MME/day, concurrent benzodiazepines) 1
• For patients with opioid use disorder, offer medication-assisted treatment (buprenorphine or methadone with behavioral therapies) 1

Common Pitfalls to Avoid

1. Starting with opioids: The evidence shows opioids have limited long-term effectiveness for chronic noncancer pain, with mounting evidence of addiction and overdose risks 2
2. Prescribing extended-release opioids initially: Always start with immediate-release formulations 1
3. Inadequate monitoring: Failure to reassess regularly leads to unrecognized harm
4. Treating pain in isolation: Chronic pain requires addressing psychological, social, and functional dimensions through interdisciplinary care 6
5. Ignoring substance use risk: All patients require risk assessment before opioid initiation 4

Team-Based Approach

Develop interdisciplinary teams for patients with complex chronic pain, especially those with co-occurring substance use or psychiatric disorders 4. The team should include pain specialists, physical therapists, psychologists, and when appropriate, palliative care specialists 4.